 |
|
Training Courses on Clinical Practices
-Mastering the Characteristics of Viruses into Clinical Practices |
|
| |
| Precautions of hospital infection have been always worldwide concerned issues. This track will discuss the evidence-based precautions. Through expert’s re-evaluaion and rationalizations, you can learn major Problems of hospital infection in the early 21st century. With good traing, it will be possible to lower the hospital infection rate by increasing medical in place of surgical treatments, the development of low invasive surgeries and/or progress of immunotherapy instead of chemotherapy. Strategies for hospital infection control and prevention in the early 21st century are based on evidence-based precautions, effective organization, accurate surveillance, compliance of precautions, risk management, outcome evaluation and feedback, economical evaluation, sterility assurance and peer review for these strategies. |
| |
| Course 1: Clinical Perspectives in Emerging Viruses Infection Control and Management |
| |
| This course will invite clinical expert to teach how to grasp professional skills in clinical practice for in emerging viral infectious prevention and control for doctors and nurse and healthcare personnel. The topics will be covered as the following: |
| |
|
Key issues include: |
| |
1) infections in compromised patients; 2) emergence of resistant virus; 3) terminal infection; 4) bloodborne virus infection; 5) neonatal virus infections; 6) emerging and re-emerging viral diseases. |
| |
|
|
Other Important Strategies with Emerging Viral Diseases Include: |
| |
1) Hygiene Plan; 2) How to use personal protective equipment; 3) How to safely handle and dispose sharps; 4) How to safely handle and dispose chemical waste;5) How to manage blood and bodily fluids (Spillages ;Collecting, Handling and Labelling of Specimens);6) How to decontaminate equipment (Cleaning;Disinfection;Sterilisation);7) How to achieve and maintain a clean clinical environment; 8) How to appropriately use indwelling devices;9)How to manage accidental exposure to blood-borne virus |
| |
|
| If you are qualified lecturer and can offer your expertise to share with our colleagues and medical professionals, you can submit your training course here. |
|
| |
| Course 2: Offshore IND Clinical Trial Strategies |
| |
| With the increasing outsourcing strategies practiced by overseas pharmaceutical and biopharmaceutical companies, there are great opportunities for cost-effective clinical trials in China. However, the Challenges have been also faced, i.e., how to meet the IND approval requirement by FDA on valid trial Basis. This course provides in-depth lecture and instruction on how to perform efficient and effective clinical trials in China. |
| |
|
Policy on Off-Shore Clinical Trials of New Antivirals in China |
|
Patient Recruitment Methods |
|
Chinese GCP Resources Available for Big Pharmas |
|
How to Execute Valid Clinical Trials in China |
|
Timeline Management for Antiviral IND in China |
|
Data and Documentation Management |
|
Cost Consideration vs Quality Assurance |
| |
|
If you are qualified lecturer and can offer your expertise to share with our colleagues and medical professionals, you can submit your training course here. |
|
| |
| Course 3: Current Treatment and Management of Viral Infectious Disease with New Prescription Drugs |
| |
| This Course will offer you how to use new prescription drugs rationally, which will cover valuable instructions and precautions on current prescription drugs: |
| |
| Topic 1: Viral Disorder and Therapeutic Approaches |
|
Commom Viral Infections |
|
Vaccines or Antiviral Drugs |
|
Inhibition of Viral Infection of Cells |
|
Inhibition of Viral Processing |
| |
|
| If you are qualified lecturer and can offer your expertise to share with our colleagues and medical professionals, you can submit your training course here. |
|
| |
| Topic 2: Current Treatment in clinical practice for Viral Infectious Diseases |
|
Human Immunodeficiency Virus |
| |
1) HIV Reverse Transcriptase Inhibitors; 2) HIV Protease Inhibitors ; 3) HIV Fusion Inhibitors |
|
Hepatitis Viruses |
| |
1) Vaccine Treatments ; 2) Cytokines ; 3) Antiviral Agents |
|
Herpes Viruses |
| |
1) Viral Replication Inhibitors |
|
Human Papilloma Viruses |
|
Respiratory Viruses |
| |
1) Vaccines; 2) Neuraminidase Inhibitors; 3) Antibodies; 3) Inosine Monophosphate Dehydrogenase Inhibitors |
| |
|
| If you are qualified lecturer and can offer your expertise to share with our colleagues and medical professionals, you can submit your training course here. |
|
| |
| Topic 3: Safety Issues and Post-prescription Management |
|
New Prescription Drug Information Format to Improve Patient Safety |
|
Drugs to treat HIV/AIDS, HCV, SARS Avian Flu and other Severe Infectious Diseases |
|
To Manage the risks of medication use and reduce medical errors, |
|
Make Sure Read and Understand the Newly Designed Package Insert |
|
Check Out References to Detailed, Toxicity, Safety and Efficacy Information. |
|
Examine The date of initial product approval |
|
Case Studies of Management of Side Effects |
|
Skills and Responsibilities to Follow up with the Patients |
| |
|
| If you are qualified lecturer and can offer your expertise to share with our colleagues and medical professionals, you can submit your training course here. |
|
